<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Significant advances in the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) include the implementation of prevention efforts aimed at delaying progression of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> to overt <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (DM) and the development of new classes of blood <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering medications to supplement existing therapies </plain></SENT>
<SENT sid="1" pm="."><plain>While the current management approach for T2DM continues to encompass traditional drugs that focus on Î²-cell failure and/or <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, newer agents that target other defects (eg, incretin deficiency/resistance) are increasingly incorporated </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, the effect of therapies on associated comorbidities (eg, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo>) has become an additional therapeutic focus </plain></SENT>
<SENT sid="3" pm="."><plain>This article provides a discussion of specific pharmacologic agents, based on guidelines from the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association/European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> and relevant clinical studies </plain></SENT>
<SENT sid="4" pm="."><plain>An extensive update on the newest drugs (eg, incretin-based therapies, amylin <z:chebi fb="4" ids="48705">agonists</z:chebi>) and managed care aspects of <z:mp ids='MP_0002055'>diabetes</z:mp> care is also included </plain></SENT>
</text></document>